Author: admin

“Artificial Pancreas Device System Market”

DelveInsight’s ‘Artificial Pancreas Device System Market Insight, Competitive Landscape and Market Forecast,  2030’ report delivers an in-depth understanding of Artificial Pancreas Device System and the historical and forecasted Artificial Pancreas Device System market trends, globally, which comprises of North America, Europe, APAC, and RoW.

The report on the Artificial Pancreas Device System market offers a comprehensive review of the device system, including its applications, advantages, and limitations. Furthermore, it delves into market segment shares and regional assessments, presenting both qualitative and quantitative data (in USD million, spanning 2021- 2030) for all covered segments.

Request for a sample copy of the Artificial Pancreas Device System Market report @ https://www.delveinsight.com/sample-request/artificial-pancreas-device-system-market

The Artificial Pancreas Device System market report offers an overview of Artificial Pancreas Device System, applications of Artificial Pancreas Device System as well as its advantages and limitations. Additionally, the report provides insight on the Artificial Pancreas Device System market share by segments, along with assessment of market share by regions, the qualitative and quantitative data will be provided for all the segments in the scope. Moreover, the report also covers the market drivers, market challenges and restraints, and opportunities, along with the impact COVID-19 has had on this market.

Artificial Pancreas Device Systems Overview

An artificial pancreas is a system made of three parts that work together to mimic how a healthy pancreas controls blood glucose, also called blood sugar, in the body. An artificial pancreas is mainly used to help people with type 1 diabetes.

In type 1 diabetes, the pancreas does not produce insulin. People with type 1 diabetes control their blood glucose level by checking it and taking insulin, either by injection or through an insulin infusion pump, several times a day. An artificial pancreas automatically monitors your blood glucose level, calculates the amount of insulin you need at different points during the day, and delivers it.

Most artificial pancreas systems require you to count and enter the amount of carbohydrates you consume at mealtime. These are called “hybrid” artificial pancreas systems, because some of the insulin is given automatically and some is given based on the information you enter. These systems help control blood glucose levels throughout the day and night, making it easier for people with type 1 diabetes to keep their blood glucose level in range. Keeping blood glucose levels in range will prevent other health problems from developing and may improve daily life for people with type 1 diabetes.

Read more about the operations & working of Artificial Pancreas Device System @ https://www.delveinsight.com/report-store/artificial-pancreas-device-system-market

Artificial Pancreas Device System: Market Analysis

The Artificial Pancreas Device System market segmentation illustrates the global Artificial Pancreas Device System market along with the market segmentation. Furthermore, the Artificial Pancreas Device System market report will provide the regional level cross-segmentation quantitative data. Moreover, the assessment is done on how the market is expected to rise in the study period, at a significant CAGR.

Interested in knowing how the Artificial Pancreas Device Systems Market will be growing by  2030? Click to get a snapshot: https://www.delveinsight.com/sample-request/artificial-pancreas-device-system-market

Artificial Pancreas Device System Companies

Key Artificial Pancreas Device System companies involved in manufacturing and production are making a significant growth to the advancement of these devices. To boost their market position, they also engage in mergers and acquisitions. Some of the key Artificial Pancreas Device System companies operating actively in the Artificial Pancreas Device System market include Medtronic, Animas Corporation (Johnson & Johnson), Beta Bionics, Inc., Johnson & Johnson, Defyme, Dexcom, MedTech, Tandem Diabetes Care, Semma Therapeutics (Vertex Pharmaceuticals), TypeZero Technologies (Dexcom, Inc), Pancreum, GE Healthcare, Philips; SunTech Medical, Inc., Omron Healthcare, Spacelabs Healthcare, American Diagnostic Corporation, Hill-Rom Service, Midmark, Cardinal Health, Medline Industries and others.

Artificial Pancreas Device System Report Highlights

1. The report also reviews the detailed global historical and forecasted Artificial Pancreas Device System market including assessing the outreach in America, Europe, APAC, and Rest of World (RoW).
2. The report helps in developing business strategies by understanding trends shaping and driving the global Artificial Pancreas Device System market.
3. The impact of COVID-19 on the Artificial Pancreas Device System market will be discussed in detail in the report.

Key Takeaways from the Artificial Pancreas Device System Market Report Study

1. Artificial Pancreas Device System Market size analysis for current market (2023), and Artificial Pancreas Device System market forecast for 5 years
2. The effect of the COVID-19 pandemic on the Artificial Pancreas Device System market is significant. To capture and analyze suitable indicators, our experts are closely watching the Artificial Pancreas Device System market.
3. Top key product/services/technology developments, merger, acquisition, partnership, joint venture happened for the last 3 years in the Artificial Pancreas Device System market.
4. Key companies dominating the Global Artificial Pancreas Device System Market.
5. Various opportunities available for the other competitor in the Artificial Pancreas Device System Market space.
6. What are the top performing segments? How these segments will perform?
7. Which are the top-performing regions and countries in the current Artificial Pancreas Device System market scenario?
8. Which are the regions and countries where companies should have concentrated on opportunities for Artificial Pancreas Device System market growth in the coming future?

To read more about which region is leading the market growth in the Artificial Pancreas Device System market, get a snapshot of the Artificial Pancreas Device System market report @ https://www.delveinsight.com/report-store/artificial-pancreas-device-system-market

Table of Contents

1. Artificial Pancreas Device System Market Report Introduction

2. Artificial Pancreas Device System Market Executive summary

3. Regulatory and Patent Analysis

4. Artificial Pancreas Device System Market Key factors analysis

5. Artificial Pancreas Device System Porter’s Five Forces Analysis

6. COVID-19 Impact Analysis on Artificial Pancreas Device System Market

7. Artificial Pancreas Device System Market layout

8. Artificial Pancreas Device System Global Company Share Analysis – Key 3-5 Companies

9. Artificial Pancreas Device System Company and Product Profiles

10. PROJECT APPROACH

11. KOL Views

12. DelveInsight Capabilities

13. Disclaimer

14. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Artificial Pancreas Device System Market: Revolutionizing Diabetes Management, Expected to Grow at a CAGR of 18.94% by Delveinsight | GE Healthcare; Philips; SunTech Medical, Omron Healthcare

“Metastatic Melanoma Pipeline”

As per DelveInsight’s assessment, globally, Metastatic Melanoma pipeline constitutes 75+ key companies continuously working towards developing 75+ Metastatic Melanoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

The Metastatic Melanoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

“Metastatic Melanoma Pipeline Insight 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Metastatic Melanoma Market.

Some of the key takeaways from the Metastatic Melanoma Pipeline Report:

• Metastatic Melanoma Companies across the globe are diligently working toward developing novel Metastatic Melanoma treatment therapies with a considerable amount of success over the years. 
• Metastatic Melanoma companies working in the treatment market are TILT Biotherapeutics, AiVita Biomedical, Immuneering Corporation, Ultimovacs ASA, MPyxis Oncology, Evaxion Biotech, HUYABIO International, LLC., IO Biotech, Regeneron Pharmaceuticals, and others, are developing therapies for the Metastatic Melanoma treatment 

• Emerging Metastatic Melanoma therapies in the different phases of clinical trials are- TILT 123, AV-MEL-1, IMM-1-104, UV1, APX005, EVX 01, HBI-8000, IO102-IO103, Fianlimab, and others are expected to have a significant impact on the Metastatic Melanoma market in the coming years.   
• In July 2022, “A Phase III Trial of Fianlimab(REGN3767, Anti-LAG-3) + Cemiplimab Versus Pembrolizumab in Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma” is the name of the trial that Regeneron Pharmaceuticals started.
• In July 2022, The US FDA has approved an investigational new drug application for OBX-115, Obsidian’s main engineered tumor infiltrating lymphocyte (TIL) treatment candidate, to be studied in a Phase I clinical study sponsored by MD Anderson. Obsidian Therapeutics, Inc. made this announcement. OBX-115 is the result of an arrangement announced in 2020 that was created in partnership with MD Anderson. The intended single-arm, open-label, first-in-human Phase I research will assess the safety and initial effectiveness of OBX-115 as a monotherapy in adult patients with metastatic melanoma who have relapsed or are not responding to previous anti-PD-1 antibody-containing treatment regimens.
• In July 2022, According to a statement released by Bristol Myers Squibb, the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has suggested that the fixed-dose combination of relatlimab and nivolumab be approved for the first-line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumor cell PD-L1 expression < 1%. The CHMP opinion will now be reviewed by the European Commission (EC), which has the power to approve medications for the European Union (EU).
• In late July 2022, Iovance successfully had a pre-BLA meeting with the US FDA. Regarding the potency assay matrix and follow-up time for the clinical efficacy data from Cohorts 2 and 4 of the C-144-01 clinical study, the FDA gave positive response. The clinical and safety dataset was deemed adequate by the FDA for BLA assessment. This month, Iovance will start a rolling BLA filing for lifileucel in metastatic melanoma; the submission will be finished in the fourth quarter.
• In June 2022, Sanofi and Immunocore Holdings Plc signed a clinical trial cooperation and supply agreement. As per the agreement, as part of Sanofi’s ongoing Phase I/II study, the company will assess its precisely PEGylated, engineered version of IL-2, SAR444245, in combination with Immunocore’s novel bispecific protein targeting gp100, known as KIMMTRAK, in patients with HLA-A*02:01 positive advanced unresectable or metastatic skin cancers.
• In March 2022, After PD-1 inhibitor treatment failed, the US FDA awarded Fast Track designation to 7HP349. This is the primary clinical-stage immunostimulant from 7Hill Pharma, and it is intended to be used in conjunction with a CTLA-4 inhibitor to treat patients with metastatic or unresectable malignant melanoma.
• In March 2022, The FDA authorized the use of Opdualag (nivolumab and relatlimab-rmbw) by the Bristol-Myers Squibb Company in patients with metastatic or incurable melanoma who are 12 years of age or older in adults and pediatric patients. The medication is a fixed-dose combination of nivolumab, an antibody that blocks programmed death receptor-1, and relatlimab, an antibody that blocks LAG-3.
• In January 2022, Immunocore reported that KIMMTRAK (tebentafusp-tebn) has been approved by the US Food and Drug Administration to treat adult patients with unresectable or metastatic uveal melanoma (mUM) who test positive for HLA-A*02:01. In February 2021, the FDA gave KIMMTRAK Breakthrough Therapy Designation for unresectable or metastatic uveal melanoma.Four weeks before the designated PDUFA date of February 23, 2022, the approval was given.

Metastatic Melanoma Overview

There are numerous medications in the Metastatic Melanoma pipeline at the moment. Among the most prominent medications for this indication are TILT 123, AV-MEL-1, IMM-1-104, UV1, APX005, EVX 01, HBI-8000, IO102-IO103, Fianlimab, and a few more. Current clinical studies and ongoing research could alter the industry.

Get a Free Sample PDF Report to know more about Metastatic Melanoma Pipeline Therapeutic Assessment- https://www.delveinsight.com/report-store/metastatic-melanoma-pipeline-insight

Emerging Metastatic Melanoma Drugs Under Different Phases of Clinical Development Include:

• TILT 123: TILT Biotherapeutics
• AV-MEL-1: AiVita Biomedical
• IMM-1-104: Immuneering Corporation
• UV1: Ultimovacs ASA
• APX005: MPyxis Oncology
• EVX 01: Evaxion Biotech
• HBI-8000: HUYABIO International, LLC.
• IO102-IO103: IO Biotech
• Fianlimab: Regeneron Pharmaceuticals

Metastatic Melanoma Route of Administration

Metastatic Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Metastatic Melanoma Molecule Type

Metastatic Melanoma Products have been categorized under various Molecule types, such as

• Oligonucleotide
• Peptide
• Small molecule

Metastatic Melanoma Pipeline Therapeutics Assessment

• Metastatic Melanoma Assessment by Product Type
• Metastatic Melanoma By Stage and Product Type
• Metastatic Melanoma Assessment by Route of Administration
• Metastatic Melanoma By Stage and Route of Administration
• Metastatic Melanoma Assessment by Molecule Type
• Metastatic Melanoma by Stage and Molecule Type

DelveInsight’s Metastatic Melanoma Report covers around 75+ products under different phases of clinical development like

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Metastatic Melanoma product details are provided in the report. Download the Metastatic Melanoma pipeline report to learn more about the emerging Metastatic Melanoma therapies

Some of the key companies in the Metastatic Melanoma Therapeutics Market include:

Key companies developing therapies for Metastatic Melanoma are – Evaxion Biotech, InxMed, AiVita Biomedical, Iovance Biotherapeutics, Viralytics, Merck & Co., Neon Therapeutics, BioNTech, Bristol-Myers Squibb, Ono Pharmaceuticals, Cytovation AS, Biocad, Apexigen, Checkmate Pharmaceutical, Nektar therapeutics, HUYABIO International, LLC.,  IO Biotech,  Bristol Myers Squibb, Karyopharm Therapeutics, Zucero Therapeutics, GlaxoSmithKline,  Tesaro, Inc., Ultimovacs ASA, Eucure (Beijing) Biopharma Co., Ltd, Incyte Corporation, Philogen S.p.A., Ascentage Pharma, Exelixis/Ipsen, NovoCure Ltd., Hoffman-La-Roche, Provectus Biopharmaceuticals, BerGenBio ASA, Idera Pharmaceuticals, Celgene Corporation, Novartis, and others.

Metastatic Melanoma Pipeline Analysis:

The Metastatic Melanoma pipeline report provides insights into 

• The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Melanoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Melanoma Treatment.
• Metastatic Melanoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Metastatic Melanoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Melanoma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Metastatic Melanoma drugs and therapies

Metastatic Melanoma Pipeline Market Drivers

Improving Healthcare Infrastructure, emergence of effective immune therapies are some of the important factors that are fueling the Metastatic Melanoma Market.

Metastatic Melanoma Pipeline Market Barriers

However, lack of cost-effective treatment, side effects associated with the treatment and other factors are creating obstacles in the Metastatic Melanoma Market growth.

Scope of Metastatic Melanoma Pipeline Drug Insight    

• Coverage: Global
• Key Metastatic Melanoma Companies: TILT Biotherapeutics, AiVita Biomedical, Immuneering Corporation, Ultimovacs ASA, MPyxis Oncology, Evaxion Biotech, HUYABIO International, LLC., IO Biotech, Regeneron Pharmaceuticals, and others
• Key Metastatic Melanoma Therapies: TILT 123, AV-MEL-1, IMM-1-104, UV1, APX005, EVX 01, HBI-8000, IO102-IO103, Fianlimab, and others
• Metastatic Melanoma Therapeutic Assessment: Metastatic Melanoma current marketed and Metastatic Melanoma emerging therapies
• Metastatic Melanoma Market Dynamics: Metastatic Melanoma market drivers and Metastatic Melanoma market barriers 

Request for Sample PDF Report for Metastatic Melanoma Pipeline Assessment and clinical trials

Table of Contents

1. Metastatic Melanoma Report Introduction

2. Metastatic Melanoma Executive Summary

3. Metastatic Melanoma Overview

4. Metastatic Melanoma- Analytical Perspective In-depth Commercial Assessment

5. Metastatic Melanoma Pipeline Therapeutics

6. Metastatic Melanoma Late Stage Products (Phase II/III)

7. Metastatic Melanoma Mid Stage Products (Phase II)

8. Metastatic Melanoma Early Stage Products (Phase I)

9. Metastatic Melanoma Preclinical Stage Products

10. Metastatic Melanoma Therapeutics Assessment

11. Metastatic Melanoma Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Metastatic Melanoma Key Companies

14. Metastatic Melanoma Key Products

15. Metastatic Melanoma Unmet Needs

16 . Metastatic Melanoma Market Drivers and Barriers

17. Metastatic Melanoma Future Perspectives and Conclusion

18. Metastatic Melanoma Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Metastatic Melanoma Pipeline and Therapies 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight | TILT Bio, AiVita Biomedical

“Non-small Cell Lung Cancer Pipeline”

NSCLC pipeline constitutes 135+ key companies continuously working towards developing 150+ Non-small Cell Lung Cancer treatment therapies, analyses DelveInsight

DelveInsight’s ‘Non-small Cell Lung Cancer Pipeline Insight 2024‘ report provides comprehensive global coverage of available, marketed, and pipeline NSCLC therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Non-small cell lung cancer pipeline domain.

To know more about the Non-small Cell Lung Cancer Market report offerings, click here: NSCLC Market Insight

Key Takeaways from the Non-small Cell Lung Cancer Pipeline Report

• Over 150+ NSCLC pipeline therapies are in various stages of development, and their anticipated acceptance in the Non-small cell lung cancer market would significantly increase market revenue. 
• Some of the Non-small cell lung cancer companies developing novel drug candidates to improve the NSCLC treatment landscape include BridgeBio Pharma, Daiichi Sankyo, EMD Serono, Merck, Xuanzhu Biopharmaceutical, Bayer, GeneScience Pharmaceuticals, InventisBio, Apollomics, Abbvie, Pfizer, Eli Lilly and Company, BioNTech SE, Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Innovent Biologics, Imugene, Ono Pharmaceutical/Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb, Surface Oncology, Inhibrx, Sinocelltech, Mirati Therapeutics, REVOLUTION Medicines, Yong Shun Technology Development, Iovance Biotherapeutics, Galecto Biotech, and others.
• Promising Non-small cell lung cancer therapies in various stages of development include INBRX-106, Datopotamab deruxtecan, Bintrafusp alfa, Patritumab deruxtecan, GB 1211, BBP 398, Cofetuzumab pelidotin, Abemaciclib, BNT 116, JMT101, RMC-4630, MGY 825, Adagrasib, JDQ443, TGRX 326, CKD 702, Citarinostat, IBI 110, XZP 3621, BAY 2927088, SRF388, ABBV 514, Gentuximab injection, Befotertinib, Geptanolimab, Naporafenib, IMU-201, Binimetinib, HS 10241, APX005M, Finotonlimab, Encorafenib, Autologous tumour infiltrating lymphocytes, and others.
• In Oct 2022, eftilagimod alpha has been given a fast-track designation by the FDA for use as the first-line treatment for patients with stage IIIB/IV non-small cell lung cancer when combined with pembrolizumab.
• In Oct 2022, BerGenBio announced that they had begun the phase Ib/IIa trial evaluating bemcentinib in first-line non-small cell lung cancer patients with STK11 mutations.
• In May 2022, BridgeBio Pharma and Bristol Myers Squibb (BMS) entered an exclusive license agreement for developing and marketing BBP-398 in oncology. An inhibitor of SHP2, BBP-398, was created through a partnership with the Therapeutics Discovery division of The University of Texas MD Anderson Cancer Center, US. Under the deal, BMS will make upfront and milestone payments of up to $905m to BridgeBio.

Request a sample and discover the recent breakthroughs happening NSCLC pipeline landscape in @ Non-small Cell Lung Cancer Pipeline Assessment Report

Non-small Cell Lung Cancer Overview

About 85% of all cases of lung cancer are non-small-cell lung cancer (NSCLC), which includes all epithelial lung cancers besides small-cell lung cancer (SCLC). NSCLC tumors come in three different varieties: a) Adenocarcinoma begins in cells that produce mucus and other substances inside air sacs, frequently in the outer regions of your lungs. It is the most prevalent form of lung cancer in people under 45 who smoke, nonsmokers, and both.

The common NSCLC symptoms include chest pain, wheezing, weight loss, shortness of breath, coughing up blood, and others. Several imaging tests such as X-ray, MRI, PET Scans, CT Scans, and others are used for NSCLC diagnosis. Apart from imaging tests, other tests used for NSCLC diagnosis include sputum cytology, bronchoscopy, and mediastinoscopy. 

Non-small Cell Lung Cancer Pipeline Analysis: Drug Profile

Datopotamab deruxtecan: Daiichi Sankyo

Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2-directed ADC. Datopotamab deruxtecan is one of three leading ADCs in Daiichi Sankyo’s oncology pipeline and one of the most advanced programs in AstraZeneca’s ADC scientific platform. Datopotamab deruxtecan is made up of a humanized anti-TROP2 IgG13 monoclonal antibody developed in collaboration with Sapporo Medical University, which is linked to several topoisomerases I inhibitor payloads, an exatecan derivative via tetrapeptide-based cleavable linkers.

MRTX849: Mirati Therapeutics

Adagrasib (MRTX849) is an investigational, highly selective, and potent oral small-molecule inhibitor of KRASG12C that is optimized for long-term target inhibition, which may be important in treating KRASG12C-mutated cancers because the KRASG12C protein regenerates every 24-48 hours. Adagrasib is being tested in patients with advanced KRASG12C-mutated solid tumors, such as NSCLC, colorectal cancer, and pancreatic cancer, as a monotherapy and in combination with other anti-cancer therapies.

Non-small Cell Lung Cancer Therapies and Key Companies

• Datopotamab deruxtecan: Daiichi Sankyo
• JDQ443: Novartis
• MRTX849: Mirati Therapeutics
• INBRX-106: Inhibrx
• GB 1211: Galecto Biotech
• BBP 398: BridgeBio Pharma
• TGRX 326: Shenzhen TargetRx
• SRF388: Surface Oncology
• ABBV 514: AbbVie

Learn more about the NSCLC emerging pipeline therapies @ Non-small Cell Lung Cancer Clinical Trial

Non-small Cell Lung Cancer Pipeline Therapeutics Assessment

• By Product Type
• Monotherapy
• Combination Therapy
• By Stage
• Discovery
• Pre-Clinical
• Phase I
• Phase II
• Phase III
• Pre-registration
• By Route of Administration
• Intranasal
• Intrathecal
• Intravenous
• Oral
• Parenteral
• Intramuscular
• Transdermal
• By Molecule Type
• Antisense oligonucleotide
• Gene therapy
• Hormones
• Neuropeptides
• Oligonucleotides
• Small Molecule
• Triglyceride

Scope of the Non-small Cell Lung Cancer Pipeline Report 

• Coverage: Global 
• Key Non-small Cell Lung Cancer Companies: BridgeBio Pharma (NASDAQ: BBIO), Daiichi Sankyo, EMD Serono (ETR: MRK), Merck (NYSE: MRK), Abbvie (NYSE: ABBV), Pfizer (NYSE: PFE), Eli Lilly and Company (NYSE: LLY), BioNTech SE (NASDAQ: BNTX), Shenzhen TargetRx, Taiho Pharmaceutical, Chong Kun Dang, Innovent Biologics, Xuanzhu Biopharmaceutical, Bayer (ETR: BAYN), GeneScience Pharmaceuticals, InventisBio, Apollomics, Imugene (ASX: IMU), Ono Pharmaceutical/Pierre Fabre, Jiangsu Hengrui Medicine Co., Bristol-Myers Squibb (NYSE: BMY), Surface Oncology (NASDAQ: SURF), Inhibrx (NASDAQ: INBX), Sinocelltech, Mirati Therapeutics (NASDAQ: MRTX), REVOLUTION Medicines (NASDAQ: RVMD), Yong Shun Technology Development, Iovance Biotherapeutics (NASDAQ: IOVA), Galecto Biotech (NASDAQ: GLTO), and others.
• Key Non-small Cell Lung Cancer Pipeline Therapies: INBRX-106, Datopotamab deruxtecan, Bintrafusp alfa, Patritumab deruxtecan, GB 1211, BBP 398, Cofetuzumab pelidotin, Abemaciclib, BNT 116, JMT101, RMC-4630, MGY 825, Adagrasib, JDQ443, TGRX 326, CKD 702, Citarinostat, IBI 110, XZP 3621, BAY 2927088, SRF388, ABBV 514, Gentuximab injection, Befotertinib, Geptanolimab, Naporafenib, IMU-201, Binimetinib, HS 10241, APX005M, Finotonlimab, Encorafenib, Autologous tumour infiltrating lymphocytes, and others.

Dive deep into rich insights for NSCLC emerging therapies and assessment, visit @ Non-small Cell Lung Cancer Emerging Therapies

Table of Contents

1. Introduction

2. Executive Summary

3. Overview

4. Non-small Cell Lung Cancer Pipeline Therapeutics

5. Late Stage Non-small Cell Lung Cancer Products (Phase III)

6. Mid Stage Non-small Cell Lung Cancer Products (Phase II)

7. Early Stage Non-small Cell Lung Cancer Products (Phase I/II)

8. Preclinical Stage Products

9. Discovery Stage Products

10. Non-small Cell Lung Cancer Therapeutic Assessment

11. Inactive Non-small Cell Lung Cancer Products

12. Collaborations Assessment- Licensing / Partnering / Funding

13. Non-small Cell Lung Cancer Unmet Needs

14. Non-small Cell Lung Cancer Market Drivers and Barriers

15. Appendix

16. About DelveInsight

For further information on the NSCLC current pipeline therapeutics, reach out @ Non-small Cell Lung Cancer Therapeutics Assessment

 About Delveinsight: 

DelveInsight Business Research is a leading Market Research, and Business Consultant focused purely on Healthcare. It helps pharma companies by providing them with end-to-end services to solve their business problems.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-small Cell Lung Cancer Pipeline Analysis 2024: Drugs and Companies Insight Report: NSCLC Therapeutic Analysis, MOA and ROA by DelveInsight

“Vagus Nerve Stimulator Market”

Vagus Nerve Stimulators Market By Product Type (Invasive VNS Devices and Non-Invasive VNS Devices), Application (Migraine, Epilepsy, Depression, and Others), End-User (Hospitals, Specialty Clinics, and Others), and Geography is expected to grow at a steady CAGR (forecast period- 2023-2028) owing to increasing prevalence of neurological disorders and growing popularity of non-invasive VNS devices.

The global vagus nerve stimulators market was valued at USD 426.22 million in 2022, growing at a CAGR of 9.06% during the forecast period from 2023 to 2028 to reach USD 717.17 million by 2028.

The demand for vagus nerve stimulators is witnessing a surge primarily due to the rising prevalence of neurological diseases such as epilepsy, headache disorders such as migraine, and others that have proven to receive benefit from VNS therapy, increasing popularity of VNS therapy as an alternative or even conjunctive treatment in cases where drug resistance develops, growing research in studying the effects of VNS on other indications such as tinnitus and chronic pain besides the approved ones, technological advancements leading to the development of new products such as non-invasive VNS devices thereby boosting the growth of the vagus nerve stimulators market during the forecast period from 2023-2028.

Some of the key market players operating in the Vagus Nerve Stimulator market include LivaNova (NASDAQ: LIVN), Soterix Medical Inc, MicroTransponder Inc, Parasym Ltd, electroCore (NASDAQ: ECOR), tVNS Technologies GmbH, and others.

DelveInsight’s “Vagus Nerve Stimulator Market Insight & Forecast” report will offer an in-depth understanding of the Vagus Nerve Stimulator market, further benefiting the competitors or stakeholders operating in the Vagus Nerve Stimulator arena.

Vagus Nerve Stimulator Overview

A vagus nerve stimulator is a pacemaker like device which comes with an implantable programmable generator that is implanted in the chest wall and delivers electrical impusles to the vagus nerve in the neck thereby stimulating the vagus nerve and providing relief to patients.

Interested to know more about the functioning of Vagus Nerve Stimulator- Visit @ Vagus Nerve Stimulator Operations & Working.

Vagus Nerve Stimulator Market Insights

Among all the regions, North America is estimated to account for the largest share in the vagus nerve stimulators market. The key driving factors of the North America vagus nerve stimulators market are high prevalence of epilepsy, depression in the region, increasing disposable income, and rising investments and big collaborative expansions by key players in the region. Moreover, the conducive regulatory environment in the region are expected to establish the dominance of North America VNS market in the overall global landscape.

One of the key driving factors of the United States vagus nerve stimulators market is the interplay of various factors in the country. This domination is due to the increase in epileptic population, increasing prevalence of headache disorders such as migraine, and depression in the country. Furthermore, extensive research and development activities pertaining to product development and conducive regulatory environment further helps product manufacturers to generate more revenue from the country.

For instance, as per the data cited by the National Headache Association (2022), approximately 40 million American are living with migraine and headache disorders in the country. Therefore, the presence of large patient population suffering from migraine and headache disorders correlates to the presence of a potential patient population that may resort to using VNS devices as a treatment method, thus driving the product demand in the nation. Moreover, increasing epileptic population is also expected to drive the demand for vagus nerve stimulators in the country. For instance, as per the data provided by the Centers for Disease Control and Prevention (2020), in 2015, about 3.4 million people across the nation were diagnosed with epilepsy of which 470,000 were children. As mentioned by the International League Against Epilepsy, one-third of epileptic patient population continue to have seizures despite being on anti-seizure medication. This presents another opportunity for VNS devices as they have been reported and approved for medical use for treating drug-resistant epilepsy.

Also, advanced product launches and commercialization agreements among the key companies are further expected to fuel the market. For instance, in August 2021, the US Food and Drug Administration approved drug-free rehabilitation system intended to treat moderate to severe upper extremity motor deficits associated with chronic ischemic stroke—a stroke caused by a blockage of blood flow to the brain with long-lasting symptoms the first-of-its kind VNS device- the MicroTransponder Vivistim Paired VNS System. Thus, the interplay of all the aforementioned factors are likely to fuel the market growth of vagus nerve stimulators in the United States during the forecast period

Besides United States, product development activities in Canada also provide supportive growth opportunities for the North America vagus nerve stimulators market. For instance, the Canadian Health regulatory body Health Canada authorized the Dolphin vagus nerve stimulator for emergency use in the treatment of COVID-19 induced acute respiratory distress syndrome.

Thus, all these activities point towards the presence of conducive growth environment in the North American region, ultimately influencing the market growth of this regional market.

To read more about why North America is leading the market growth in the Vagus Nerve Stimulator market, get a snapshot of the Vagus Nerve Stimulator market report.

Vagus Nerve Stimulator Market Dynamics

The vagus nerve stimulators market is experiencing an increase in product demand for a variety of reasons with one of the key reasons being the rising prevalence of neurological disorders. As per the data cited by the World Health Organization (WHO) (2022), over 50 million people across the globe suffer from epilepsy. The source further stated that the estimated proportion of the general population with active epilepsy (i.e. persistent seizures or that require treatment) at any given time is between 4 and 10 per 1000 people. Additionally, in another factsheet by the WHO, it was stated that approximately 264 million people suffer from depression globally. Neurological indications such as epilepsy and depression can be extremely debilitating for patients and are often become refractory to pharmacological treatments. Moreover, pharmacological treatments in such indications are often accompanied with severe side-effects.

Owing to these, an alternative approach such as vagus nerve stimulation has been a preferred mode of treatment in drug-resistant cases of depression, epilepsy as well as it is also being administered in combination with pharmacological treatments in order to provide synergistic effect to patients. Vagus nerve stimulation has been reported to provide positive results in terms of preventing seizures in epileptic patients. Additionally, many studies reported that patients who received vagus nerve stimulation for epilepsy, showed clinical improvement with depression unrelated to the effect of the VNS on their seizures with nearly  40-50% improvement in patients with non-psychotic major depression.

Moreover, with more positive results being reported concerning the VNS therapy, more research is being conducted on different disease areas which may further expand the application of vagus nerve stimulation in coming years. For instance, several studies are ongoing in studying the effects of VNS on tinnitus, irritable bowel syndrome, and chronic pain among other indications. This further presents an opportunity for making significant headway in the VNS market in the near future.

However, procedure-related complications and high cost of these devices may be confining factors for the vagus nerve stimulators market growth.

Along with the factors mentioned above, the vagus nerve stimulators market witnessed a period of slow growth due to the COVID-19 pandemic. The lockdown implemented by various governments worldwide to curb the spread of the COVID-19 infection resulted in suspension of various surgeries and outpatient consultations across all medical specialties including specifically impacting elective procedures. This led to a considerable decrease in the demand for VNS devices as VNS procedures were classified under elective procedures. Furthermore, the implementation of global lockdown in varying degrees further affected the procurement and supply chain. However, the approval of various COVID-19 vaccines and the implementation of mass vaccination programs have paved the way for resumption of vagus nerve stimulators demand, thereby providing a positive growth environment for the vagus nerve stimulators market during the forecast period.

Recent Breakthroughs in Vagus Nerve Stimulator Market:

• In August 2021, the US Food and Drug Administration approved the MicroTransponder Vivistim Paired VNS System, a one-of-its-kind, drug rehabilitation system with the intention to treat moderate to severe upper extremity motor deficits associated with chronic ischemic stroke.
• In March 2020, LivaNova received the CE Mark approval for their Vagus Nerve Stimulation Therapy® (VNS Therapy) System, Symmetry™ for difficult-to-treat depression.

Key Players Proactively Working In the Vagus Nerve Stimulator Market

Key Vagus Nerve Stimulator companies involved in manufacturing and production are making significant growth in the advancement of these devices. To boost their market position, they also engage in mergers and acquisitions. Some of the key Vagus Nerve Stimulator companies operating actively in the Vagus Nerve Stimulator market include LivaNova, Soterix Medical Inc, MicroTransponder Inc, Parasym Ltd, electroCore, tVNS Technologies GmbH and others.

Request for Sample Report to know more about: Vagus Nerve Stimulator companies

Scope of the Vagus Nerve Stimulator Market Report:

• Geography Covered: Global
• Key Vagus Nerve Stimulator Companies: LivaNova, Soterix Medical Inc, MicroTransponder Inc, Parasym Ltd, electroCore, tVNS Technologies GmbH and others.
• Market Segmentation by Product Type: Invasive VNS Devices And Non-Invasive VNS Devices
• Market Segmentation by Application: Migraine, Epilepsy, Depression, And Others
• Market Segmentation By End-User: Hospitals, Specialty Clinics, And Others
• Market Segmentation by Geography: North America, Europe, Asia-Pacific, Rest of the World (Middle East, Africa, and South America)
• Porter’s Five Forces Analysis, Product Profiles, Case Studies, KOL’s Views, Analyst’s View

Table of Contents 

1. Report Introduction

2. Executive Summary

3. Regulatory and Patent Analysis

4. Key Factors Analysis

5. Vagus Nerve Stimulator Porter’s Five Forces Analysis

6. COVID-19 Impact Analysis on Vagus Nerve Stimulator Market

7. Vagus Nerve Stimulator Market Layout

8. Vagus Nerve Stimulator Global Company Share Analysis – Key 3-5 Companies

9. Vagus Nerve Stimulator Companies and Product Profiles

10. Project Approach

11. KOL Views

12. DelveInsight Capabilities

13. Disclaimer

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Vagus Nerve Stimulator Market Expected To Grow at a CAGR Of 9.06%, Asserts Delveinsight | Companies – Livanova, Soterix Medical Inc, Microtransponder Inc, Parasym Ltd